BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is to drive the company's people-focused social impact initiatives.   Holding this position is Sarah Hoit, who has a personal connection to Alzheimer's, the neurodegenerative disease which is the focus of BioVie's clinical research efforts.

BioVie complements its Alzheimer's clinical research program with social impact initiatives

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in patients with mild to moderate Alzheimer's Disease (AD), and it expects to announce topline data from the trial in November or December. BioVie's shares moved higher on the news, adding 4.6% to US$3.40 in pre-market trading.

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

CARSON CITY, Nev., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the last patient has completed the last visit at week 30 in its multicenter, randomized, placebo-controlled Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer's Disease (AD).

BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

CARSON CITY, NV / ACCESSWIRE / September 20, 2023 / As researchers continue to hunt for better treatments for neurodegenerative disease, one of the biggest breakthroughs in decades has been the realization that chronic inflammation may be playing a key role in the onset and progression of debilitating diseases like Alzheimer's and Parkinson's disease. That's led biotechs like BioVie (NASDAQ:BIVI) to turn the focus to treatments that block or alter inflammation as a way to also stop the neurodegeneration causing the progressively worsening symptoms.

BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation

CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Cantor Fitzgerald Global Healthcare Conference, to be held in New York, NY, September 26-28, 2023.

BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference

BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer's Disease, highlighting the preliminary baseline metabolic and inflammation characteristics of the study population. The data was presented as a poster titled “Metabolic Dysregulation in Probable Alzheimer's Disease” by BioVie's chief medical officer Dr.

BioVie presents Alzheimer's study data on patient's baseline characteristics

Data from Phase 3 Trial of NE3107 Presented as Poster at the 148 th American Neurological Association Annual Meeting

BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease

In 2022, BioVie had reported impressive data from a small Phase 2 trial in Alzheimer's. In October-November 2023, the company will report topline data from its ongoing Phase 3 trial in Alzheimer's. The reported baseline data of the patients in the Phase 3 trial appears to match the drug's mechanism of action.

BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Benefit Investors

CARSON CITY, Nev., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is hosting today a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer's Disease. The event will take place today at 2:30pm ET. To register, click here.

BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer's Disease Today, September 7, 2023

Galera Therapeutics

iSpecimen

23andMe

Singular Genomics Systems

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

CARSON CITY, Nev., Aug. 31, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer's Disease. The event will take place on Thursday, September 7, 2023 at 2:30pm ET. To register, click here.

BioVie to Host Virtual KOL Event on NE3107 in Alzheimer's Disease on September 7, 2023

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround

BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

BioVie Inc (NASDAQ:BIVI) said new preclinical data characterizing its lead drug candidate NE3107's mechanism in action is being presented at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS) being held in Copenhagen, Denmark from August 27 to 31. BioVie CEO Cuong Do said that the results and analysis presented at the MDS this week added to the growing body of data for NE3107 that supports the company's core understanding of this molecule and its potential in diseases such as Parkinson's Disease (PD).

BioVie showcases promising data for NE3107 at international Parkinson's Disease event

CARSON CITY, Nev., Aug. 28, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson's Disease (PD) at the 2023 International Congress of Parkinson's Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.

BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson's Disease and Movement Disorders

Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

Soligenix

ORLANDO, FL / ACCESSWIRE / August 11, 2023 / RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET).

BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV

BioVie Inc (NASDAQ:BIVI) has issued a letter to shareholders providing an update on its progress and recent findings. The letter highlights the company's excitement and optimism regarding the Phase 3 trial for NE3107 in Alzheimer's Disease (AD), which is expected to release its results later this year.

BioVie updates on its progress and recent findings

CARSON CITY, Nev., July 18, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued the following letter to shareholders:

BioVie Issues Letter to Shareholders

BioVie Inc (NASDAQ:BIVI) presented a poster over the weekend showcasing the epigenetic basis for how its drug candidate NE3107 may have regulated specific genes in a way that delivers cognitive improvements for patients with clinical dementia.  The poster was presented Sunday at the Alzheimer's Associate's International Conference (AAIC) in Amsterdam, which is being held July 16-20.

BioVie's clinical dementia drug NE3107 shown to reduce DNA methylation

CARSON CITY, Nev., July 17, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced data from a poster detailing the epigenetic basis for how in a Phase 2 exploratory biomarker study its drug candidate NE3107 may have potentially regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements. The poster was presented yesterday at the Alzheimer's Associate's International Conference (AAIC) held in Amsterdam July 16-20, 2023.

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

BioVie Inc (NASDAQ:BIVI) announced that a poster detailing how its drug candidate NE3107 regulated specific genes in a way significantly correlated with observed cognitive and biomarker improvements will be presented at the Alzheimer's Associate's International Conference being held in Amsterdam this weekend from July 16 to 20. The company said the new data being presented shows how NE3107 could potentially change or affect the degree of methylation of specific genes correlated with various disease markers.

BioVie to present promising new data for drug candidate NE3107 at Alzheimer's conference

CARSON CITY, Nev., July 10, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster detailing the genetic basis for how its drug candidate NE3107 regulated specific genes in a manner significantly correlated with observed cognitive and biomarker improvements will be presented this weekend at the Alzheimer's Associate's International Conference (AAIC) to be held in Amsterdam July 16-20, 2023.

BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

BioVie Inc (NASDAQ:BIVI) announced that baseline data from a multicenter, randomized, placebo-controlled Phase 3 study of its Alzheimer's Disease treatment was presented at the 83rd Scientific Sessions of the American Diabetes Association over the weekend in San Diego.  The company's treatment, NE3107, is an oral small molecule, blood-brain permeable anti-inflammatory insulin sensitizer that binds extracellular signal-regulated kinase.

BioVie presents Phase 3 study of Alzheimer's treatment at San Diego medical conference

Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting Baseline Data from Phase 3 Trial of NE3107 Presented as Poster at the American Diabetes Association Annual Meeting

News for BioVie Inc Stock (BIVI)